Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment

Inclusion Criteria: 1. Confirmed diagnosis of Crohn's disease ( Lennard -Jones criteria ) 2. Active Crohn's disease in the last six months to the inclusion defined as : CDAI? 220 and endoscopic or radiological criteria of activity 3. Refractory or intolerance to conventional therapy including corticosteroids , immunomodulators and anti-tumor necrosis factor-alpha 4. Presence of visible lesions by endoscopy 5. Acceptance to participate in the study and written informed consent Exclusion Criteria: 1. No injuries in pre-screening resonance 2. Pregnancy, lactation or women of childbearing age not taking appropriate contraceptive measures 3. Patients HIV + and Hepatitis C Virus + Hepatitis B Virus + 4. Serious concomitant disease: * Renal failure with creatinine clearance \< 40ml / min * Heart disease: congestive heart failure with ejection fraction \< 45 % , atrial fibrillation treated with oral anticoagulants, uncontrolled ventricular arrhythmias , pericarditis , pleural effusion with hemodynamic * Neoplasms or myelodysplasia * Psychiatric disorders including alcohol and drugs 5. Symptoms attributable to fibrotic strictures in Crohn's disease at the discretion of the investigators 6. Diarrhea attributable to " short bowel syndrome" 7. Active infection , including tuberculosis 8. Participation in research studies of new drugs in the 3 months prior to inclusion. 9. Vaccination with live/attenuated germs in the previous 3 months 10. Personal history of cancer (active or complete remission) or known family history of hereditary cancer. 11. Patients in whom , after observation of the state of their veins , these are considered inaccessible and impossible to perform apheresis